Updated Guidelines for Metastatic Hormone-sensitive Prostate Cancer: Abiraterone Acetate Combined with Castration Is Another Standard

Publikation

Updated Guidelines for Metastatic Hormone-sensitive Prostate Cancer: Abiraterone Acetate Combined with Castration Is Another Standard

Wissenschaftlicher Artikel/Review - 02.11.2017

Mottet Nicolas, van den Bergh Roderick C N, Rouvière Olivier, van der Poel Henk G, Lam Thomas B, Grummet Jeremy P, Gillessen Sommer Silke, Bourke Liam, Briers Erik, De Santis Maria, Cornford Philip

Zitation

Mottet N, van den Bergh R, Rouvière O, van der Poel H, Lam T, Grummet J, Gillessen Sommer S, Bourke L, Briers E, De Santis M, Cornford P. Updated Guidelines for Metastatic Hormone-sensitive Prostate Cancer: Abiraterone Acetate Combined with Castration Is Another Standard. Eur Urol 2017

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Eur Urol 2017

Veröffentlichungsdatum

02.11.2017

eISSN (Online)

1873-7560

Kurzbeschreibung/Zielsetzung

Addition of docetaxel to androgen deprivation therapy (ADT) was recommended for patients with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC), who are fit enough to receive docetaxel. Two recently published trials showed that the addition of abiraterone acetate plus prednisone to ADT has a clear survival benefit and acceptable overall tolerance, and should be considered as another standard of care for newly diagnosed mHSPC.